56 results
8-K
EX-10.2
UBX
Unity Biotechnology Inc
29 Sep 21
Entry into a Material Definitive Agreement
5:26pm
, investigation or appeal taken from the foregoing by or before any court or governmental, administrative or other regulatory agency or body or the SEC … not be unreasonably withheld. Such indemnity shall remain in full force and effect regardless of any investigation made by or on behalf
8-K
EX-1.1
UBX
Unity Biotechnology Inc
22 Aug 22
UNITY Biotechnology Announces Pricing of Upsized Underwritten Public Offering
4:13pm
, there is no action, suit, proceeding, inquiry or investigation before or brought by any Governmental Entity (including, without limitation, any action, suit … proceeding, inquiry or investigation before or brought by the U.S. Food and Drug Administration (the “FDA”) or the European Medicines Agency (the “EMA
8-K
EX-99.1
UBX
Unity Biotechnology Inc
30 Mar 20
UNITY Biotechnology Announces Start of New CEO and New Employment Inducement Grants
5:05pm
to time with the Securities and Exchange Commission. This press release concerns drug candidates that are under clinical investigation and which have
8-K
EX-99.1
UBX
Unity Biotechnology Inc
2 Mar 20
UNITY Biotechnology Appoints Anirvan Ghosh, PhD as Chief Executive Officer
5:28pm
investigation and which have not yet been approved for marketing by the U.S. Food and Drug Administration. They are currently limited by Federal law
8-K/A
EX-99.2
yesbja6q
7 Jul 21
Financial Statements and Exhibits
8:00am
8-K
EX-99.1
yvlbw6x
6 Nov 19
UNITY Biotechnology, Inc. Reports Third Quarter 2019 Financial Results and Business Updates
4:05pm
8-K
EX-99.1
svebn334o63xh oj
7 Aug 19
UNITY Biotechnology, Inc. Reports Second Quarter 2019 Financial Results and Program Updates
4:05pm
8-K
EX-99.1
qegn8u
25 Feb 20
UNITY Biotechnology Provides Pipeline and Business Updates
8:01am
8-K
EX-99.1
4oez we6y
6 Jul 21
UNITY Biotechnology Announces Positive Data from Phase 1 Clinical Trial of UBX1325 in Patients with Advanced Vascular Eye Disease
7:11am
8-K
EX-99.2
lg7j5h sr0r
6 Jul 21
UNITY Biotechnology Announces Positive Data from Phase 1 Clinical Trial of UBX1325 in Patients with Advanced Vascular Eye Disease
7:11am
8-K
EX-99.1
02oqz acj8
11 May 21
UNITY Biotechnology, Inc. Reports First Quarter 2021 Financial Results and Business Updates
8:06am
8-K
EX-99.2
8gilxd2tpdt0i1fa
12 Aug 22
UNITY Biotechnology Announces Positive Data in Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema
7:18am
8-K
EX-99.2
kn3ysm49tg3h
24 Apr 23
UNITY Biotechnology Announces Positive 48-Week Results from Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema
7:05am
S-3
EX-1.2
anw5tsb1ph 7u3fq
3 Jun 19
Shelf registration
9:18am
8-K
EX-99.2
lwuv eth66o1x
1 Nov 22
UNITY Biotechnology Announces Positive 24-Week Data from Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema
7:00am